Takeda Pharmaceutical Company Limited (TAK)
| Previous Close | 14.80 |
| Open | 14.87 |
| Bid | 14.88 x 4000 |
| Ask | 14.89 x 2900 |
| Day's Range | 14.85 - 14.94 |
| 52 Week Range | 12.58 - 16.39 |
| Volume | |
| Avg. Volume | 2,179,390 |
| Market Cap | 47.136B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 45.06 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.58 (3.95%) |
| Ex-Dividend Date | Mar 27, 2024 |
| 1y Target Est | N/A |
- CNW Group
Vatroslav Mateljic Appointed General Manager of Takeda Canada
Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company.
- Business Wire
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass., August 07, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).3 ADZYNMA is now the first and only enzyme replacement therapy in the European Union (EU) specifically for the treatment of cTTP.3,4 This approval includes confirmation of orphan medicinal product des
- Business Wire
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
OSAKA, Japan, July 31, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Growth & Launch Products driving Core growth at CER and more than offsetting revenue impact resulting from significant losses of exclusivity that occurred in the previous fiscal year.
